Intrinsiqq
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) Insider Trading

Last 12 months

Insiders bought $85.1M and sold $21.8M on the open market.

2% of the selling was scheduled in advance under 10b5-1 plans. Director Joshua Ruch sold $6.09M on Nov 24, 2025, 17% of their stake, outside a plan.

Net open-market
+$63.3M
4 buys · 33 sales
Under a 10b5-1 plan
2%
of the value sold
Insiders who bought / sold
2 / 4
executives and directors
Last open-market buy
Jun 2026
Jun 5, 2026

Get an email when WGS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 16No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 3,728 at avg $97.61
    $364k
    7.7% of stake
  • Sep 16No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 10,501 at avg $97.61
    $1.03M
    8.3% of stake
  • Sep 9No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 1,285 at $84.22
    $108k
    3.0% of stake
  • Sep 9No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 3,692 at $84.22
    $311k
    3.3% of stake
  • Sep 1No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 372 at $83.84
    $31k
    0.9% of stake
  • Jun 16No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 3,729 at avg $60.76
    $227k
    8.5% of stake
  • Jun 16No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 10,501 at avg $60.76
    $638k
    9.1% of stake
  • Jun 9No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 1,266 at $53.77
    $68k
    3.4% of stake
  • Jun 9No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 3,639 at $53.77
    $196k
    3.6% of stake
  • Jun 4 – 5
    Eli Casdin
    Director · bought 200,000 at avg $55.55
    $11.1M
    5.2% of stake
  • Jun 1No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 369 at $51.74
    $19k
    1.0% of stake
  • May 18 – 20
    Casdin Partners Master Fund, L.p.
    Large holder · bought 500,000 at avg $42.92
    $21.5M
    15% of stake
  • May 13 – 15
    Keith A. Meister
    Director · bought 351,273 at avg $39.19
    $13.8M
    7.3% of stake
  • May 7 – 11
    Keith A. Meister
    Director · bought 1,205,147 at avg $38.84
    $46.8M
    34% of stake
  • Apr 29No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 392 at $65.19
    $26k
    1.1% of stake
  • Apr 29No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 2,172 at avg $65.19
    $142k
    2.3% of stake
  • Mar 26No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 8,818 at avg $63.17
    $557k
    20% of stake
  • Mar 26No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 46,933 at avg $63.17
    $2.96M
    34% of stake
  • Mar 16No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 5,706 at avg $76.80
    $438k
    17% of stake
  • Mar 16No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 17,179 at avg $76.80
    $1.32M
    23% of stake
  • Mar 9No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 1,280 at $86.75
    $111k
    5.5% of stake
  • Mar 9No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 3,678 at $86.75
    $319k
    7.6% of stake
  • Mar 3 – 5
    Keith A. Meister
    Director · bought 169,521 at avg $79.40
    $13.5M
    5.0% of stake
  • Mar 4No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 6,187 at avg $78.61
    $486k
    25% of stake
  • Mar 4No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 25,459 at avg $78.61
    $2M
    40% of stake
  • Mar 2No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 287 at $77.52
    $22k
    2.9% of stake
  • Feb 410b5-1 plan
    Bryan Dechairo
    Chief Operating Officer · sold 5,961 at avg $85.70
    $511k
    100% of stake
  • Feb 2No plan
    Bryan Dechairo
    Chief Operating Officer · sold 3,413 at avg $99.53
    $340k
    36% of stake
  • Jan 29No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 317 at avg $93.99
    $30k
    3.3% of stake
  • Jan 29No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 1,653 at $94.00
    $155k
    9.1% of stake
  • Dec 16, 2025No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 3,855 at avg $143.87
    $555k
    31% of stake
  • Dec 16, 2025No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 10,857 at avg $143.89
    $1.56M
    43% of stake
  • Dec 9, 2025No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 1,266 at $159.28
    $202k
    19% of stake
  • Dec 9, 2025No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 3,639 at $159.28
    $580k
    36% of stake
  • Dec 1, 2025No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 377 at $162.54
    $61k
    8.2% of stake
  • Nov 24, 2025No plan
    Joshua Ruch
    Director · sold 38,000 at avg $160.37
    $6.09M
    17% of stake
  • Oct 29, 2025No plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 388 at $136.54
    $53k
    9.4% of stake
  • Oct 29, 2025No plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 2,158 at avg $136.54
    $295k
    39% of stake
  • Sep 30, 202510b5-1 plan
    Kevin Feeley
    CHIEF FINANCIAL OFFICER · sold 6,609 at avg $108.38
    $716k
    66% of stake
  • Sep 30, 202510b5-1 plan
    Katherine Stueland
    CHIEF EXECUTIVE OFFICER · sold 12,858 at avg $108.17
    $1.39M
    88% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch WGS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Health Services

Spot a number that looks wrong? Check it in WGS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing WGS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.